2nd Quarter - Report

BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY

Firm
Client
Income
—
Expenses
$1,130,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Lobbied regarding intellectual property rights in trade agreements and international negotiations. Saudi Arabia, Saudi Food and Drug Authority, lobbied Congress regarding pharmaceutical patent infringement issues.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); SENATE; Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

H.R. 1, Tax Cuts and Jobs Act, regarding all pharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); SENATE; Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS)

Bills named: H.R. 1 (115th)

Copyright/Patent/Trademark CPT

No bill, lobbied on patent troll issues regarding biopharmaceutical patents. H.R. 1892, Bipartisan Budget Act, regarding all biopharmaceutical provisions

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); SENATE; Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR)

Bills named: H.R. 1892 (115th)

Health Issues HCR

No bill, lobbied to raise awareness about Atrial Fibrillation and stroke prevention. No bill, lobbied regarding biosimilars issues including naming, labeling and interchangeability. H.R. 1245 and S. 469, Affordable and Safe Prescription Drug Importation Act, lobbied regarding all biopharmaceutical provisions. H.R. 1703, Medical Product Communications Act of 2017, regarding all biopharmaceutical related provisions H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, regarding all biopharmaceutical related provisions No bill, lobbied for changes to the 340B Drug Discount Program. H.R. 4710, 340B PAUSE Act, lobbied regarding all biopharmaceutical provisions. H.R. 4392, a bill to repeal the HOPPS final regulation related to changes in the payment amount for certain drugs under the 340B program, lobbied regarding all biopharmaceutical provisions. H.R. 2026, the Pharmaceutical Information Exchange (PIE) Act of 2017, lobbied regarding all biopharmaceutical provisions. S. 2312, Helping Ensure Low-Income Patients have Access to Care and Treatment (HELP) Act, regarding all pharmaceutical related provisions. S.2453, Ensuring the Value of the 340B Program Act of 2018, regarding all pharmaceutical related provisions. H.R. 5598 340B Optimization Act, regarding all pharmaceutical related provisions. H.R. 6071 SERV Communities Act, regarding all pharmaceutical related provisions. H.R. 6240, Drug Discount Accountability Act, regarding all pharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: Commerce, Dept of (DOC); SENATE; U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 5598 (115th), H.R. 6071 (115th), H.R. 1703 (115th), H.R. 2026 (115th), H.R. 2851 (115th), S. 469 (115th), H.R. 4392 (115th), H.R. 1245 (115th), H.R. 6240 (115th), S. 2312 (115th), S. 2453 (115th), H.R. 4710 (115th)

Medicare/Medicaid MMM

H.R. 849, S. 260, S. 251 Protecting Seniors Access to Medicare Act, lobbied regarding all biopharmaceutical related provisions. S.771, Improving Access To Affordable Prescription Drugs Act, lobbied regarding all biopharmaceutical related provisions. S.348, Prescription Drug and Health Improvement Act of 2017, lobbied regarding all biopharmaceutical related provisions. S.637, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017, lobbied regarding all biopharmaceutical related provisions. No bill, American Patients First Prescription Drug Blueprint,regarding all biopharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: Health & Human Services, Dept of (HHS); Commerce, Dept of (DOC); Health Resources & Services Administration (HRSA); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 771 (115th), H.R. 849 (115th), S. 260 (115th), S. 251 (115th), S. 637 (115th), S. 348 (115th)

Budget/Appropriations BUD

American Health Care Act, regarding all biopharmaceutical related provisions. Continuing Budget Resolution, lobbied regarding all biopharmaceutical provisions. Better Care Reconciliation Act, regarding all biopharmaceutical related provisions. S. 1771, Department of Labor, HHS and Education Appropriations Act, regarding all pharmaceutical related provisions. H.R. 1625, Consolidates Appropriations Act, regarding all pharmaceutical related provisions.

LobbyistCovered position, as disclosed
LANE PENRY —
CHRISTOPHER PERNIE —
PAUL ANTHONY WILLIAMS —

Contacted: U.S. Trade Representative (USTR); Health Resources & Services Administration (HRSA); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: S. 1771 (115th), H.R. 1625 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.